The Associations of Plasma Biomarkers of Inflammation With Histopathologic Lesions, Kidney Disease Progression, and Mortality—The Boston Kidney Biopsy Cohort Study
暂无分享,去创建一个
S. Waikar | J. Bonventre | H. Rennke | V. Sabbisetti | I. Stillman | R. Palsson | I. Schmidt | A. Weins | Anand Srivastava | Astrid Weins | Anand Srivastava
[1] H. Nagaraja,et al. Urinary Soluble CD163: a Novel Noninvasive Biomarker of Activity for Lupus Nephritis. , 2020, Journal of the American Society of Nephrology : JASN.
[2] P. Kimmel,et al. Plasma Biomarkers of Tubular Injury and Inflammation Are Associated with Chronic Kidney Disease Progression in Children. , 2020, Journal of the American Society of Nephrology : JASN.
[3] S. Weisbord,et al. Kidney Biomarkers of Injury and Repair as Predictors of Contrast-Associated AKI: A Substudy of the PRESERVE Trial. , 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[4] D. Leaf,et al. Soluble Urokinase Receptor and Acute Kidney Injury. , 2020, The New England journal of medicine.
[5] A. Heinzel,et al. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease , 2019, Diabetologia.
[6] Jennifer K. Sun,et al. A Signature of Circulating Inflammatory Proteins and Development of End Stage Renal Disease in Diabetes , 2019, Nature Medicine.
[7] J. Kellum,et al. Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury: A Randomized Clinical Trial , 2018, JAMA.
[8] B. Kestenbaum,et al. Association of Soluble TNFR-1 Concentrations with Long-Term Decline in Kidney Function: The Multi-Ethnic Study of Atherosclerosis. , 2018, Journal of the American Society of Nephrology : JASN.
[9] J. Coresh,et al. Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD. , 2018, Clinical journal of the American Society of Nephrology : CJASN.
[10] Anand Srivastava,et al. The Prognostic Value of Histopathologic Lesions in Native Kidney Biopsy Specimens: Results from the Boston Kidney Biopsy Cohort Study. , 2018, Journal of the American Society of Nephrology : JASN.
[11] P. Libby,et al. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease. , 2018, Journal of the American College of Cardiology.
[12] M. Kretzler,et al. OP-NDTJ180031 1942..2019 , 2018 .
[13] L. Cantley,et al. Breast Regression Protein-39/Chitinase 3-Like 1 Promotes Renal Fibrosis after Kidney Injury via Activation of Myofibroblasts. , 2017, Journal of the American Society of Nephrology : JASN.
[14] A. Galecki,et al. Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease. , 2017, Kidney international.
[15] L. Fried,et al. Plasma Biomarkers and Kidney Function Decline in Early and Established Diabetic Kidney Disease. , 2017, Journal of the American Society of Nephrology : JASN.
[16] M. Burnier,et al. Safety and Tolerability Study of an Intravenously Administered Small Interfering Ribonucleic Acid (siRNA) Post On-Pump Cardiothoracic Surgery in Patients at Risk of Acute Kidney Injury , 2017, Kidney international reports.
[17] Y. Çiçek,et al. The relationship between serum YKL-40 levels and arterial stiffness in patients with ankylosing spondylitis. , 2017, Acta reumatologica portuguesa.
[18] A. Didangelos,et al. Extracellular matrix proteomics identifies molecular signature of symptomatic carotid plaques , 2017, The Journal of clinical investigation.
[19] A. Levey,et al. Urine Fibrosis Markers and Risk of Allograft Failure in Kidney Transplant Recipients: A Case-Cohort Ancillary Study of the FAVORIT Trial. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[20] J. Himmelfarb,et al. The CKD Classification System in the Precision Medicine Era. , 2017, Clinical journal of the American Society of Nephrology : CJASN.
[21] Sudhir V. Shah,et al. Association of Urinary Biomarkers of Inflammation, Injury, and Fibrosis with Renal Function Decline: The ACCORD Trial. , 2016, Clinical journal of the American Society of Nephrology : CJASN.
[22] F. Kronenberg,et al. Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis. , 2016, JAMA.
[23] A. Quyyumi,et al. Soluble Urokinase Receptor and Chronic Kidney Disease. , 2015, The New England journal of medicine.
[24] Eric A. Miller,et al. Linkage of NCHS Population Health Surveys to Administrative Records From Social Security Administration and Centers for Medicare Medicaid Services. , 2015, Vital and health statistics. Ser. 1, Programs and collection procedures.
[25] W. Knowler,et al. Tumor necrosis factor receptors 1 and 2 are associated with early glomerular lesions in type 2 diabetes , 2015, Kidney international.
[26] Y. Kim,et al. Circulating Tumor Necrosis Factor α Receptors Predict the Outcomes of Human IgA Nephropathy: A Prospective Cohort Study , 2015, PloS one.
[27] Yusuke Suzuki,et al. Circulating TNF Receptors 1 and 2 Are Associated with the Severity of Renal Interstitial Fibrosis in IgA Nephropathy , 2015, PloS one.
[28] T. Mayadas,et al. TNF receptors: signaling pathways and contribution to renal dysfunction. , 2015, Kidney international.
[29] W. Knowler,et al. Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes , 2014, Kidney international.
[30] Y. Kim,et al. Circulating TNF Receptors Are Significant Prognostic Biomarkers for Idiopathic Membranous Nephropathy , 2014, PloS one.
[31] L. Cantley,et al. Chitinase-like protein Brp-39/YKL-40 modulates the renal response to ischemic injury and predicts delayed allograft function. , 2013, Journal of the American Society of Nephrology : JASN.
[32] T. Mayadas,et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. , 2012, Journal of the American Society of Nephrology : JASN.
[33] E. Salido,et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis , 2011, Nature Medicine.
[34] H. J. Kim,et al. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. , 2010, American journal of physiology. Renal physiology.
[35] Zhigang Zhang,et al. Interval censoring , 2010, Statistical methods in medical research.
[36] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[37] P. Harris,et al. Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.
[38] L. Tarnow,et al. YKL-40, a Marker of Inflammation and Endothelial Dysfunction, Is Elevated in Patients With Type 1 Diabetes and Increases With Levels of Albuminuria , 2009, Diabetes Care.
[39] M. Pencina,et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.
[40] Y. Li,et al. Role of ADAM17 in the ectodomain shedding of TNF‐α and its receptors by neutrophils and macrophages , 2007, Journal of leukocyte biology.
[41] D. Adu,et al. The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease. , 2006, Kidney International.
[42] G. Remuzzi,et al. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. , 2006, The Journal of clinical investigation.
[43] S. Meng,et al. Oxidative Stress and Antioxidant Treatment in Hypertension and the Associated Renal Damage , 2005, American Journal of Nephrology.
[44] M. Pencina,et al. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation , 2004, Statistics in medicine.
[45] Jianguo Sun,et al. Generalized log‐rank test for mixed interval‐censored failure time data , 2004, Statistics in medicine.
[46] P. Pattynama,et al. Complication rate and diagnostic yield of 515 consecutive ultrasound-guided biopsies of renal allografts and native kidneys using a 14-gauge Biopty gun , 2003, European Radiology.
[47] D. Goeddel,et al. TNF-R1 Signaling: A Beautiful Pathway , 2002, Science.
[48] A. Schmaier,et al. Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. , 2001, Blood.
[49] C. Alpers,et al. J Am Soc Nephrol 11: 2231–2242, 2000 Expression of the Chemokine Monocyte Chemoattractant Protein-1 and Its Receptor Chemokine Receptor 2 in Human , 2022 .
[50] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[51] Jon A. Wellner,et al. A Hybrid Algorithm for Computation of the Nonparametric Maximum Likelihood Estimator from Censored Data , 1997 .
[52] J Sun,et al. A non-parametric test for interval-censored failure time data with application to AIDS studies. , 1996, Statistics in medicine.
[53] L. Gesualdo,et al. Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: a pathogenetic role in interstitial monocytes recruitment. , 1996, Journal of the American Society of Nephrology : JASN.
[54] B. Haller,et al. Mortality prediction in stable hemodialysis patients is refined by YKL-40, a 40-kDa glycoprotein associated with inflammation. , 2018, Kidney international.
[55] J. Navarro-González,et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. , 2015, Journal of the American Society of Nephrology : JASN.
[56] R. Atkins,et al. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. , 2006, Kidney international.